Table 3

Resource utilisation in the ITT patient group

Pre-omalizumab (n=218)Post-omalizumab (n=218)Mean difference (95% CI)
A&E visits/patient1.12 (1.71)0.37 (0.91)−0.75 (−0.99 to −0.52), p<0.001
Inpatient admissions/patient1.24 (1.64)0.56 (1.33)−0.68 (−0.85 to −0.51), p<0.001
Outpatient visits/patient*4.60 (2.48)1.60 (2.07)−3.00 (−3.43 to −2.58), p<0.001
Bed days/patient6.61 (9.73)3.39 (8.49)−3.22 (−4.31 to −2.12), p<0.001
Day case visits/patient0.03 (0.18)0.03 (0.19)0.00 (−0.04 to 0.03), p>0.01
  • Data are presented as mean (SD).

  • *Excluding visits for omalizumab administration.

  • ITT: intention to treat.